Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy.

Journal: BMJ oncology
Published Date: Feb 1, 2024

Abstract

OBJECTIVE: Fast progression (FP) represents a desperate situation for advanced non-small cell lung cancer (NSCLC) patients undergoing immune checkpoint inhibitor therapy. We aimed to develop a predictive framework based on machine learning (ML) methods to identify FP in advanced NSCLC patients using blood test biomarkers.

Authors

  • Jian-Guo Zhou
    Department of Oncology, The second affiliated Hospital of Zunyi Medical University, Zunyi, People's Republic of China.
  • Jie Yang
    Key Laboratory of Development and Maternal and Child Diseases of Sichuan Province, Department of Pediatrics, Sichuan University, Chengdu, China.
  • Haitao Wang
    Department of Gastrointestinal Surgery, Zhongshan People's Hospital, Zhongshan, Guangdong, China.
  • Ada Hang-Heng Wong
    AW Medical Co Ltd, Macau, People's Republic of China.
  • Fangya Tan
    Department of Analytics, Harrisburg University of Science & Technology, Harrisburg, Pennsylvania, USA.
  • Xiaofei Chen
    Oncology Biometrics, AstraZeneca, Gaithersburg, Maryland, USA.
  • Si-Si He
    Department of Oncology, The second affiliated Hospital of Zunyi Medical University, Zunyi, People's Republic of China.
  • Gang Shen
    Department of Oncology, The second affiliated Hospital of Zunyi Medical University, Zunyi, People's Republic of China.
  • Yun-Jia Wang
    Department of Oncology, The second affiliated Hospital of Zunyi Medical University, Zunyi, People's Republic of China.
  • Benjamin Frey
    Translational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen & Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Rainer Fietkau
    Department of Radiation Oncology, Universitätsklinikum Erlangen & Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Markus Hecht
    Department of Radiation Oncology, Saarland University Medical Center, Homburg, Germany.
  • Wenzhao Zhong
    Department of Pulmonary Surgery, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People's Republic of China.
  • Hu Ma
    Department of Oncology, The second affiliated Hospital of Zunyi Medical University, Zunyi, People's Republic of China.
  • Udo Gaipl
    Translational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen & Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals